Today Stories

Idorsia to capitalize upon the unique opportunity to transform the insomnia treatment paradigm, notably in Europe where daridorexant would be the first dual orexin receptor antagonist made available to patients with insomnia Collaboration with Syneos Health to effectively reach the primary care market in Europe and Canada Allschwil, Switzerland & Morrisville, N.C. – January 26, 2022Idorsia Ltd (SIX: IDIA), a leading Swiss biopharmaceutical company, and Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the extension of an existing collaboration to commercialize daridorexant, a novel dual orexin receptor antagonist for the treatment of insomnia across Europe and Canada. Simon Jose, Chief Commercial Officer of Idorsia, comm…

Merger continues commitment to innovation and strengthens tech-enablement and automation Frankfurt, Germany – 25 January 2022: PharmaLex Group, a leading provider of specialized services for the pharma, biotech and medtech industries worldwide, has announced a merger with leading technology and services organization for clinical and regulatory solutions, Phlexglobal. Founded in 1997, Phlexglobal provides its industry-leading and innovative electronic Trial Master File platform (PhlexTMF) and services to hundreds of global life sciences companies and AI-enabled automation solutions that allow customers to benefit from existing clinical and regulatory training models.   Phlexglobal’s staff of more than 400 people – based in the United Kingdom, the United States, India, Poland and Germany – b…

DUBAI, Arab Emirates, January 21, 2022 (Newswire.com) - AiPharma, a global biopharmaceutical company developing and commercializing innovative antiviral therapies, has completed an extensive rebranding effort in response to accelerated company growth and to reflect the business's expanded strategy. The company has undergone a significant transformation at the beginning of 2022 and has decided to relaunch its business under the new brand name Cellvera. The name Cellvera, originated from Latin, breaks down to 'cell' - which is referred to as the smallest yet fundamental unit of life in which the DNA code is being stored, and 'vera' which means true. This name represents the company and aligns with its beliefs and approach towards the science in which lies the truth of life and health encoded…

Achieved Global Recognition And Top Employer Certification In 39 Countries From Top Employers Institute® Recognition Highlights Takeda’s Unwavering Commitment To Its People OSAKA, Japan and CAMBRIDGE, Massachusetts, January 19, 2022 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it was one of only 11 companies to achieve global Top Employer® certification for 2022, marking the fifth consecutive year that it has been recognized for outstanding people policies and practices worldwide. In addition to the global certification, Takeda is also recognized as a Top Employer across four regions and 39 countries, reinforcing its steadfast commitment to create a diverse and inclusive organization that enables its people to thrive.    Established more…

Boehringer Ingelheim advances to one of eleven global top employers worldwide  Awards in 29 countries and in Europe, the Latin America, and Asia-Pacific regions  High scores in values, ethics and integrity serve as a driver for a strong corporate innovation culture  Ingelheim, Germany, January 20, 2022 – The Top Employers Institute awarded Boehringer Ingelheim for the second year in succession a “Global Top Employer”, one of the world’s eleven best employers. The award shows that the research-driven pharmaceutical company is strongly oriented to the needs and well-being of its employees. Boehringer Ingelheim has been listed among the top employers in many countries and regions for the past eight years. This year, Boehringer Ingelheim will receive the award in 29 countries, as well as…

Merger extends reach in key Italian marketplace and broadens market access expertise  Frankfurt, Germany – January 18th 2022: PharmaLex Group, a leading provider of specialized services for the pharma, biotech and medical device industries worldwide, has announced a merger with MAP Group, Italy’s leading provider of market access services.  Founded in 2010 by Elena Paola Lanati, MAP Group comprises three companies: MA Provider, MAPCOM Consulting and 3P Solution, which together deliver high-quality expertise across the product life cycle -- from negotiation strategy, to local market access, to market launch.  MAP Group’s staff of more than 70 experts support a large number of new drugs for market entry in Italy, providing integrated market access, communication and educational services. The…

COLLABORATION LEVERAGES EVOTEC'S BROAD METABOLIC EXPERTISE AND UNIQUE KIDNEY DISEASE PATIENT DATABASE AS WELL AS INTEGRATED DATA-DRIVEN DRUG DISCOVERY AND DEVELOPMENT PLATFORMS LILLY HAS THE RIGHT TO SELECT UP TO FIVE PROGRAMMES Hamburg, Germany, 18 January 2022:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered into a drug discovery collaboration with Eli Lilly and Company ("Lilly") in the field of metabolic diseases with a focus on kidney diseases and diabetes.The collaboration leverages Evotec's extensive experience and track record of delivering in the field of metabolic diseases, as well as its unique and extensive kidney disease patient database, to identify and validate promising novel targets for th…

Enables sharing of, and access to, novel datasets and tools through Eagle Genomics’ e[datascientist]™ platform Agreement will facilitate understanding of complex relationships between microbiome, food and other factors, including potential causes of health and disease Cambridge and Norwich, UK – 13 January 2022 - Today, Eagle Genomics, the Deep Tech software business pioneering the application of network science to biology, and the Quadram Institute, a world-leading institute creating new interfaces between food science, gut biology, and human health, are pleased to announce a new partnership committed to promoting the understanding of microbiome science. Building on the agreement announced in September 2021 with the Earlham Institute, a Norwich-based leader in data-intensive bioscience…

Scholarships assist students pursuing STEM fields at Historically Black Colleges and Universities (HBCUs) Supports Black and Brown teachers to boost retention and quality in the classroom Mentorship opportunities with Baxter employees will further extend impact   WASHINGTON and DEERFIELD, Ill. - 2022-01-13 The Thurgood Marshall College Fund (TMCF), the largest organization exclusively representing the Black College community, and the Baxter International Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), introduced today a new collaboration called the Baxter HBCU STEM Scholars Program. The three-year, $3.5 million initiative funds scholarships and mentoring as part of a multi-faceted approach to support students at Historically Black Colleges and Univ…

Handheld blood glucose management device designed around the specific needs of healthcare professionals working in a range of care settings First diagnostic solution at the point of care to serve as a digital platform connecting developers of digital health software and applications to healthcare professionals New system simplifies workflows and equips healthcare professionals with valuable clinical insights to deliver better patient care Basel, 12 January 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the cobas® pulse system in select countries accepting the CE Mark. The cobas® pulse system marks Roche Diagnostics’ newest generation of connected point of care solutions for professional blood glucose management. As an industry first, the cobas® pulse system combi…

The new company is focused on developing GP-2250, a novel cancer therapeutic with a unique mechanism of action BERWYN, Pa.--(BUSINESS WIRE)--Panavance Therapeutics Inc. (“Panavance”) is a new clinical-stage pharmaceutical company created to advance and develop GP-2250, a patented, novel therapeutic for the treatment of cancer and other therapeutic indications. GP-2250 is a broadly active, tumor cell selective cancer therapeutic with a unique mechanism of action that, as demonstrated in preclinical research, suppresses cancer cells by disrupting their energy metabolism—bringing about cancer cell death. Panavance’s initial clinical focus is on pancreatic cancer, and the company is conducting preclinical studies to develop GP-2250 for the treatment of other cancers and therapeutic indications…

EQT Private Equity and Goldman Sachs Asset Management committed to supporting Parexel’s Patients-First focus, track record of clinical excellence and dedication to quality Newly-appointed Board of Directors brings vast experience across life sciences, digital transformation and innovation to guide next phase of transformational journey EQT Private Equity and Goldman Sachs Asset Management to back existing management team led by CEO Jamie Macdonald BOSTON and Durham, N.C. Nov. 15, 2021 — Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, today announced the completion of its acquisition by EQT IX fund (“EQT Private Equity”) and funds managed by the Private Equity business within Goldman…

Agreement Announced on the Australian Stock Exchange and SIX Swiss Exchange 14 December, 2021 Expands CSL’s leadership across an attractive portfolio focused on Renal Disease, and Iron Deficiency Complements CSL’s existing therapeutic focus areas including Hematology and Thrombosis, Cardiovascular-Metabolic, and Transplant, and high quality pipeline CSL’s global scale, R&D capabilities and resources augment the delivery of Vifor Pharma’s products to patients globally All-cash tender offer of US$179.25 per Vifor Pharma share, representing an aggregate equity value for Vifor Pharma of US$11.7 billion / A$16.4 billion1 Tender offer is unanimously recommended for acceptance by Vifor Pharma's Board of Directors Patinex AG, Vifor Pharma's largest shareholder holding 23% of Vifor Pharma’s sh…

Accelerates the company's vision for transforming healthcare and advancing patient care worldwide – from the hospital to the home Combination creates opportunities for innovation that should drive efficiencies across care settings and help improve care outcomes Complementary products and pipeline enable broader access to care globally Expected to generate high single-digit ROIC by year five and approximately $250 million of annual pre-tax cost synergies by the end of year three  Positions Baxter for anticipated faster top- and bottom-line growth DEERFIELD, Ill. - 2021-12-13 Baxter International Inc. (NYSE:BAX), a global medtech leader, announced today it has completed its acquisition of Hillrom. Baxter paid $156.00 in cash for each outstanding share of Hillrom common sto…

Next-generation sequencing (NGS) enables a better understanding of genetic mechanisms linked to specific diseases and is helping drive personalised healthcare Preparing DNA for sequencing libraries is complex and prone to human error, which can interfere with accurate sequencing results The new AVENIO Edge System is a fully-automated solution for the sample preparation workflow, from DNA sample input to the output of sequencing-ready libraries, and supports more comprehensive testing with consistent and high quality results for precision medicine for the future Basel, 13 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the AVENIO Edge System, a core component of Roche’s strategy to advance sequencing technologies. Built on best-in-class foundational capabi…

First emergency use authorization in the United States for a COVID-19 vaccine booster in individuals 16 years and older NEW YORK & MAINZ, Germany -- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 16 years of age and older. The booster dose is to be administered at least six months after completion of the primary series and is the same formulation and dosage strength as the doses in the primary series. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209005841/en/ “Today’s decision by the FDA to further expand the Emergen…

WALTHAM, Mass., Dec. 8, 2021 -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed its acquisition of PPD, Inc. (Nasdaq: PPD), a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion. "We are very excited to officially welcome our PPD colleagues to Thermo Fisher Scientific," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. "Expanding our value proposition for our biotech and pharmaceutical customers with the addition of PPD's leading clinical research services advances our work in bringing life-changing therapies to market, benefitting patients around the world."  As previously announced, the transaction is expected to…

Part of an ongoing investigation focused on how obesity and dysregulated metabolic hormones promote prostate cancer progression and metastasis Studies aim to quantify the ability of SynDevRx MetAP2 inhibitor evexomostat (SDX-7320) to control tumor growth of castration resistant prostate cancers CAMBRIDGE, Mass.--SynDevRx, Inc., a clinical-stage biotechnology company leading the development in treatments for obesity-accelerated cancers, today announced a research collaboration with Australia’s Queensland University of Technology. The collaboration with Professor Colleen Nelson, PhD, and her team will study the role of methionine aminopeptidase 2 (MetAP2) inhibition in tumor growth in castration resistant and other treatment resistant forms of prostate cancer. Obesity and systemic metaboli…

Liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis, a systemic, progressive and fatal condition  AstraZeneca has entered into a new global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. Eplontersen is a ligand-conjugated antisense investigational medicine currently in Phase III clinical trials for amyloid transthyretin cardiomyopathy (ATTR-CM) and amyloid transthyretin polyneuropathy (ATTR-PN). It is designed to reduce the production of transthyretin (TTR protein) to treat both hereditary and non-hereditary forms of TTR amyloidosis (ATTR). The companies will jointly develop and commercialise eplontersen in the US, while AstraZeneca will develop…

The combination rapid antigen test quickly differentiates between SARS-CoV-2 and influenza viruses A and B infections, with results ready in less than 30 minutes, allowing informed decisions on patient and pandemic management decisions Affordable and small, instrument-free testing kit enables convenient use for healthcare professionals at different point of care locations and in resource-limited settings The test works seamlessly with NAVIFY® Pass, Roche’s digital solution that allows individuals and healthcare professionals to immediately store, display, and share their COVID-19 test results and vaccine status through a unique data matrix Basel, 6 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced its plans to launch the SARS-CoV-2 & Flu A/B Rapid Antigen Test for pr…